Diagnostic Value of the Biofire®in Community Acquired Pneumonia

Diagnostic Value of the Biofire® Filmarray Pneumonia Panel Compared to Conventional Sputum Culture in Critically il Patients With Pneumonia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06428318

Enrollment

Registered

2024-05-24

Start date

2023-05-15

Completion date

2024-04-30

Last updated

2024-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Brief summary

This study aimed to determine the impact value of the BioFire FilmArray Pneumonia panel compared to conventional sputum culture in critically ill patients with pneumonia.

Detailed description

the BioFire® FilmArray Pneumonia Panel (BFPP) emerges as a promising candidate for a rapid and multifaceted diagnostic approach. This study compare the diagnostic accuracy, turnaround time, and impact on antibiotic management decisions of BFPP versus conventional sputum culture in critically ill patients admitted to the ICU with suspected pneumonia.

Interventions

DIAGNOSTIC_TESTConventional Sputum culture

Sputum culture was done to patients and they received Antibiotics According to its results

DIAGNOSTIC_TESTBioFire Pneumonia Panel (BFPP)

BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients admitted to the ICU with community acquired pneumonia

Exclusion criteria

* Age less than 18 years old. * End stage malignant patients, * Patients admitted to the ICU with Acute Lung Injury (ALI). * Patients admitted to the ICU with Acute Respiratory Distress Syndrome (ARDS). * Patients with radiological findings suggesting atypical pneumonia. * Immunocompromised as defined by HIV/AIDS, known immunodeficiency, chronic steroids \> 20mg/day Prednisone equivalent, other immunosuppressants. * Solid organ or bone marrow transplant patients, cystic fibrosis. * Unstable psychiatric or psychological condition rendering the subject unlikely to be cooperative or to complete the study requirements.

Design outcomes

Primary

Measure	Time frame	Description
the ICU length of stay	Five days after admission	The potential correlation between the use of BFPP and its relation to the ICU length of stay

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026